News

New phase II data presented demonstrated that up to 77% of patients taking once-daily oral FTY720 remained free of relapses over two years. They also maintained a low

The new formulation of Rebif is said to offer substantial improvement in tolerability and reduction in antibody formation. The primary objective of the study was to compare the

Lodotra provides all the benefits of standard immediate release (IR) prednisone but has the additional advantage of reduced morning stiffness combined with a convenient dosing regimen. Patients with

Vectibix is the first human antibody developed for the treatment of patients whose colorectal cancer has spread after chemotherapy treatments. The therapy targets a protein called the epidermal

The partnership will develop compounds that specifically target the Glucose-Dependent Insulinotropic Receptor, or GDIR. The GDIR is a receptor discovered by Arena that has the potential to stimulate

Trubion is developing TRU-015 with biopharmaceutical company, Wyeth. Upon initiation of this phase IIb study and pursuant to the terms of its collaboration with Wyeth, Trubion will receive

The agreement will enable the two companies to combine a BioInvent therapeutic antibody with InNexus’ SuperAntibody Technology. The SuperAntibody Technology has been developed to improve the potency of

Teva, the world’s largest maker of generic drugs, emphasized the strength of its pipeline at a meeting for investors and analysts. CEO Israel Makov said he was very

Initial results from the study show that AeroLEF provided benefit compared to placebo. However, the difference in effectiveness between the placebo and treatment groups has not yet reached